www.genscreen.com.au

February 2010

genscreenadmin — Fri, 29 Jan 2010 06:22:53 +0000

Genscreen announces that the in-house RESET project has completed initial testing and shall be renamed “Hervian”.
The intention is to eventually outlicense the Hervian monoclonal antibody for optimisation and humanisation.
Hervian is relevant for diseases such as cancer (prostate, breast, head & neck) and multiple sclerosis.
Hervian project also includes the discovery and development of a small molecule inhibitor - designated as R200-series.
Hervain R200 is being developed as a treatment for people with chronic viral infections, including potential application for HIV, HSV, EBV and also to treat Influenza.

January 2010

genscreenadmin — Fri, 15 Jan 2010 06:02:08 +0000

Ian Dixon, CEO of Genscreen Pty Ltd, announces that Genscreen is presently having TR400 drugs sythesised by a contractor. It is anticipated that screening results will be ready for review by March 2010.
TR400 is the development lead series of Trobio Pty Ltd, a subsidiary of Genscreen Pty Ltd.
Two other development series are also under development for complementary applications - TR500 and TR600.
The intention is to outlicense TR400 as soon as a suitable partner can be found.
Genscreen Pty Ltd is a privately-held company with a portfolio of 5 projects across therapeutic applications that include cancer, MS and other diseases caused by viral infections.

December 2009

genscreenadmin — Sat, 12 Dec 2009 06:16:06 +0000

Genscreen announces the interim results of its preclinical development projects.
RESET monoclonal antibody has been produced and is ready for animal testing in cancer model.
RESET ELISA has now been developed and validated and is ready for use.
TR400 has been tested in 2-D and 3-D melanoma models and has also been tested in animal model of cancer.

August 2009

genscreenadmin — Wed, 12 Aug 2009 05:57:43 +0000

Genscreen commences work with Qubist Molecular Design (www.qubistmd.com) for the design and optimisation of TR400, TR500 and TR600 development series for Trobio project.
Trobio Pty Ltd is a subsidiary of Genscreen Pty Ltd.
Genscreen Pty Ltd is a privately-held biotechnology and drug-development company based in Melbourne Australia.

May 2009

genscreenadmin — Fri, 29 May 2009 06:09:08 +0000

Genscreen Pty Ltd announces that it has reduced its operations to concentrate on core activities.
Present core activities are shareholding in Cell Therapies Pty Ltd, preclinical drug-development subsidiary Trobio Pty Ltd and preclinical project RESET.

February 2007

resinmedia — Mon, 12 Feb 2007 15:02:46 +0000

Genscreen Pty Ltd is a privately-held company with a portfolio of 5 projects across therapeutic applications that include cancer, MS and other diseases caused by viral infections. Two new shareholders joined Genscreen this month and we welcome their contributions to our journey.

31st October 2005

resinmedia — Mon, 31 Oct 2005 14:59:28 +0000

Revision to Web site completed. The revised Genscreen web site reflects the broad range of activities of Genscreen and the existing portfolio activities.

17th September 2005

resinmedia — Sat, 17 Sep 2005 14:58:12 +0000

Genscreen announces the completion of the formation of Trobio Pty Ltd and the partnership with the tropomyosin technology of Professor Peter Gunning. Professor Gunning has agreed to be a member of the Trobio Scientific Advisory Panel, along with Associate Professor Mark Smith and Dr Ricky Johnstone.

Trobio Pty Ltd is a subsidiary of Genscreen Pty Ltd. The CEO of Genscreen, Ian Dixon, announced that Trobio was an exciting addition to the existing portfolio of Genscreen; and represented a significant opportunity for a drug development project to progress towards a Phase II trial and eventual partnership with an international partner.

17th May 2005

resinmedia — Tue, 17 May 2005 14:54:24 +0000

Genscreen announces its move to Suite 52, 12 Collins Street Melbourne.

2nd April 2005

resinmedia — Sat, 02 Apr 2005 14:53:35 +0000

The present business activities in partnership with the Peter MacCallum Cancer Centre have been transferred to Genscreen Pty Ltd. Cell Therapies Pty Ltd (www.celltherapies.com.au) is now jointly owned by Peter MacCallum Cancer Centre and Genscreen and has Mr Ray Wood as the CEO.